These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 1687191)

  • 21. Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine.
    Duncan GE; Criswell HE; McCown TJ; Paul IA; Mueller RA; Breese GR
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1027-34. PubMed ID: 3121842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of (3H)-terguride and (3H)-spiperone binding to dopamine receptors in the rat striatum.
    Valchár M; Dobrovský K; Krejcí I; Dlabac A
    Act Nerv Super (Praha); 1989 Apr; 31(1):77-9. PubMed ID: 2675526
    [No Abstract]   [Full Text] [Related]  

  • 23. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.
    Wardas J; Konieczny J; Lorenc-Koci E
    Synapse; 2001 Aug; 41(2):160-71. PubMed ID: 11400182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cocaine tolerance and cross-tolerance.
    Katz JL; Griffiths JW; Sharpe LG; De Souza EB; Witkin JM
    J Pharmacol Exp Ther; 1993 Jan; 264(1):183-92. PubMed ID: 8093724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Influence of reserpine, nialamide, l-dopa and dopamine on the analgesic effect of ethanol (author's transl)].
    Montoya G; Bardisa L
    Arch Biol Med Exp; 1970; 7(2):8-10. PubMed ID: 5538218
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of narcotic antagonists on L-dopa reversal of reserpine-induced catalepsy and blepharoptosis in mice.
    Namba MM; Quock RM; Malone MH
    Life Sci; 1981 Apr; 28(14):1629-36. PubMed ID: 7195448
    [No Abstract]   [Full Text] [Related]  

  • 27. Graphical method to determine sigmoid ligand binding in vivo at low doses.
    Swart JA; Dijkstra HA; Korf J
    J Pharmacol Methods; 1990 Apr; 23(2):97-105. PubMed ID: 1970611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reserpine-induced reduction of in vivo binding of SCH 23390 and N-methylspiperone and its reversal by d-amphetamine.
    Inoue O; Tsukada H; Yonezawa H; Suhara T; Langstrom B
    Eur J Pharmacol; 1991 May; 197(2-3):143-9. PubMed ID: 1915566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Difference in in vivo receptor binding between [3H]N-methylspiperone and [3H]raclopride in reserpine-treated mouse brain.
    Inoue O; Kobayashi K; Tsukada H; Itoh T; Langstrom B
    J Neural Transm Gen Sect; 1991; 85(1):1-10. PubMed ID: 1678266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice.
    Rubinstein M; Muschietti JP; Gershanik O; Flawia MM; Stefano FJ
    J Pharmacol Exp Ther; 1990 Feb; 252(2):810-6. PubMed ID: 2138223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of L-dopa and reserpine on in vivo binding of (3H)-SCH 23390 and (3H)-N-methylspiperone.
    Yonezawa H; Inoue O; Tsukada H; Suhara T; Itoh T; Tohgi H; Yamasaki T; Långström B
    Acta Radiol Suppl; 1991; 376():167-8. PubMed ID: 1687191
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.